Michael Amoroso Sells 1,526 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 1,526 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $10.32, for a total transaction of $15,748.32. Following the transaction, the chief executive officer now directly owns 13,772 shares in the company, valued at $142,127.04. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Precision BioSciences Price Performance

Shares of Precision BioSciences stock opened at $10.52 on Friday. Precision BioSciences, Inc. has a 12 month low of $8.25 and a 12 month high of $27.02. The business has a fifty day simple moving average of $12.55 and a two-hundred day simple moving average of $11.80.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings results on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). Precision BioSciences had a negative return on equity of 204.66% and a negative net margin of 125.84%. The business had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. On average, sell-side analysts anticipate that Precision BioSciences, Inc. will post -3.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on DTIL shares. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research note on Wednesday, April 17th. Guggenheim initiated coverage on Precision BioSciences in a research report on Tuesday, April 30th. They set a “buy” rating and a $19.00 price objective on the stock.

Institutional Trading of Precision BioSciences

A number of hedge funds have recently made changes to their positions in the stock. Tejara Capital Ltd raised its stake in Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock valued at $136,000 after buying an additional 200,000 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock valued at $1,073,000 after acquiring an additional 242,425 shares in the last quarter. Finally, Curi Wealth Management LLC raised its position in shares of Precision BioSciences by 42.0% in the 3rd quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares during the last quarter. 37.99% of the stock is owned by institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.